Molecular and clinical aspects of targeting the VEGF pathway in tumors.

Journal of Oncology
Grzegorz KorpantyRolf A Brekken

Abstract

Tumor angiogenesis is a complex process resulting from many signals from the tumor microenvironment. From preclinical animal models to clinical trials and practice, targeting tumors with antiangiogenic therapy remains an exciting area of study. Although many scientific advances have been achieved, leading to the development and clinical use of antiangiogenic drugs such as bevacizumab, sorafenib, and sunitinib, these therapies fall short of their anticipated benefits and leave many questions unanswered. Continued research into the complex signaling cascades that promote tumor angiogenesis may yield new targets or improve upon current therapies. In addition, the development of reliable tools to track tumor responses to antiangiogenic therapy will enable a better understanding of current therapeutic efficacy and may elucidate mechanisms to predict patient response to therapy.

References

Feb 1, 1971·The Journal of Experimental Medicine·J FolkmanG Williams
Nov 18, 1971·The New England Journal of Medicine·J Folkman
Feb 1, 1966·Laboratory Investigation; a Journal of Technical Methods and Pathology·B A Warren, P Shubik
Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·G L WangG L Semenza
Jun 2, 1995·The Journal of Biological Chemistry·A P LevyM A Goldberg
Jan 20, 1995·The Journal of Biological Chemistry·G L Wang, G L Semenza
Jan 12, 1996·The Journal of Biological Chemistry·T CohenB Z Levi
Nov 15, 1996·The Journal of Biological Chemistry·R S WarrenD B Donner
Feb 14, 1998·The American Journal of Cardiology·J ButlerJ R Wilson
Jul 14, 1998·The American Journal of Cardiology·S C ChengS B Feinstein
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·S HiratsukaM Shibuya
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·B OlofssonU Eriksson
May 4, 2000·The American Journal of Pathology·K PaavonenK Alitalo
Aug 19, 2000·Science·B St CroixK W Kinzler
Apr 6, 2001·The American Journal of Pathology·J L YuB L Coomber
Sep 5, 2001·Progress in Cardiovascular Diseases·G M Lanza, S A Wickline
Feb 14, 2002·Trends in Cardiovascular Medicine·Gera NeufeldYael Herzog

❮ Previous
Next ❯

Citations

Oct 21, 2011·Current Oncology Reports·Alberto J MonteroCharles Vogel
Jun 4, 2013·The Journal of Surgical Research·Annelie MollbrinkPer Stål
Jan 24, 2012·AJR. American Journal of Roentgenology·Clemens C CyranKonstantin Nikolaou
Dec 21, 2011·Nature Reviews. Clinical Oncology·Dorothy M K Keefe, Emma H Bateman
Aug 15, 2019·Cancer Biotherapy & Radiopharmaceuticals·Sara RamezaniShahrokh Yousefzadeh Chabok
May 17, 2012·Current Eye Research·Eduardo DibMichel Eid Farah

❮ Previous
Next ❯

Methods Mentioned

BETA
imaging techniques
xenografts

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Journal of Cellular Physiology
George K Michalopoulos
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
D E CressmanR Taub
© 2021 Meta ULC. All rights reserved